A landmark study has found that a single infusion of an experimental gene-editing therapy can dramatically reduce “bad” LDL cholesterol in patients with severe inherited heart risks. The trial results, published in The New England Journal of Medicine in May 2026, showed that findings from the Phase I Heart-2 clinical trial demonstrated that VERVE-102—a single-dose gene-editing therapy—successfully switched off the PCSK9 gene…
